- Home
- CNTX vs SGMT Comparison
CNTX vs SGMT Comparison
Compare CNTX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNTX | SGMT |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.5M | 164.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNTX | SGMT |
|---|---|---|
| Price | $3.13 | $5.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $6.00 | ★ $27.00 |
| AVG Volume (30 Days) | ★ 876.8K | 374.1K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $1.73 |
| 52 Week High | $3.30 | $11.41 |
Technical Indicators
Market Signals| Indicator | CNTX | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 67.82 | 45.03 |
| Support Level | $2.07 | $4.97 |
| Resistance Level | N/A | $6.49 |
| Average True Range (ATR) | 0.24 | 0.33 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 85.25 | 23.70 |
Price Performance
Historical ComparisonAbout CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.